Nitric oxide synthase inhibition exaggerates the hypotensive response to ghrelin: Role of calcium-activated potassium channels

Journal of Hypertension

Volumn 23, Issue 4, 2005, Pages 779-784

  Shinde, Urmila A ^a   Desai, Kaushik M ^a   Yu, Changhua ^a   Gopalakrishnan, Venkat ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Ghrelin; Heart rate; K+ channel; Mean arterial pressure; Nitric oxide

Indexed keywords

ACETYLCHOLINE; APAMIN; CALCIUM ACTIVATED POTASSIUM CHANNEL; CHARYBDOTOXIN; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; GHRELIN; GROWTH HORMONE SECRETAGOGUE; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; BOLUS INJECTION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENZYME INHIBITION; HEART RATE; HYPOTENSION; INFUSION; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE;

EID: 17144386607     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000163146.20330.bc     Document Type: Article

References (32)

1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660.
2. Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya H, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2001; 280:R1483-R1487.
3. Ishizaki S, Murase T, Sugimura Y, Kakiya S, Yokoi H, Tachikawa K, et al. Role of ghrelin in the regulation of vasopressin release in conscious rats. Endocrinology 2002; 143:1589-1593.
4. Matsumura K, Tsuchihashi T, Fuji K, Abe I, Iida M. Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension 2002; 40:694-699.
5. Okumura H, Nagaya N, Enomoto M, Nakagawa E, Oya H, Kanagawa K. Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J Cardiovasc Pharmacol 2002; 39:779-783.
6. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001; 104:1430-1435.
7. Wiley KE, Davenport AP. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol 2002; 136:1146-1152.
8. Lin Y, Matsumura K, Fukuhara M, Kaagiyama S, Fujii K, Iida M. Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. Hypertension 2004; 43:977-982.
9. Makino Y, Hosoda H, Shibata K, Makino I, Kojima M, Kangawa K, Kawarabayashi T. Alteration of plasma ghrelin levels associated with the blood pressure in pregnancy. Hypertension 2002; 39:781-784.
10. Henriques-Coelho T, Correia-Pinto J, Roncon-Albuquerque R Jr, Baptista MJ, Lourenco AP, Oliveira SM, et al. Endogenous production of ghrelin and beneficial effects of its exogenous administration in monocrotaline-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 2004; 287:H2885-H2890.
11. 125I-His(9)]- ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with atherosclerosis. Br J Pharmacol 2001; 134:143-149.
12. Laight DW, Desai KM, Gopaul NK, Angaard EE, Carrier MJ. Pro-oxidant challenge in vivo provokes the onset of NIDDM in the insulin resistant obese Zucker rat. Br J Pharmacol 1999; 128:269-271.
13. Ribeiro MO, Antunes E, Muscara MN, De Nucci G, Zatz R. Nifedipine prevents renal injury in rats with chronic nitric oxide inhibition. Hypertension 1995; 26:150-155.
14. Gopalakrishnan V, Liu P, Tang G, Yu C, McNeill JR, Wang R. Ghrelin and des-acyl ghrelin are the most potent vasodilators: selective activation of EDHF. Circulation 2003; 108(suppl):IV-302P.
15. Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I, Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 1996; 94:3341-3347.
16. Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am J Physiol Gastrointest Liver Physiol 2002; 283:G1074-G1081.
17. Ruiz-Marcos FM, Ortiz MC, Fortepiani LA, Nadal FJ, Atucha NM, Garcia-Estan J. Mechanisms of the increased pressor response to vasopressors in the mesenteric bed of nitric oxide-deficient hypertensive rats. Eur J Pharmacol 2001; 412:273-279.
18. Woodman OL, Wongsawatkul O, Sobey CG. Contribution of nitric oxide, cyclic GMP and K+ channels to acetylcholine-induced dilatation of rat conduit and resistance arteries. Clin Exp Pharmacol Physiol 2000; 27:34-40.
19. Zanchi A, Aubert JF, Brunner HR, Waeber B. Vascular acetylcholine response during chronic NO synthase inhibition: in vivo versus in vitro. Cardiovasc Res 1995; 30:122-129.
20. Moncada S, Rees DD, Schulz R, Palmer MJ. Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci USA 1991; 88:2166-2170.
21. Tesfamariam B, Halpern W. Endothelium-dependent and endothelium- independent vasodilation in resistance arteries from hypertensive rats. Hypertension 1988; 11:440-444.
22. Najibi S, Cowan CL, Palacino JJ, Cohen RA. Enhanced role of potassium channels in relaxations to acetylcholine in hypercholesterolemic rabbit carotid artery. Am J Physiol Heart Circ Physiol 1994; 266:H2061-H2067.
23. + is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998; 396:269-272.
24. Yamanaka A, Ishikawa T, Goto K. Characterization of endothelium-dependent relaxation independent of NO and prostaglandins in guinea pig coronary artery. J Pharmacol Exp Ther 1998; 285:480-489.
25. Tanaka Y, Hayakawa S, Imai T, Akutsu A, Hirano H, Tanaka H, et at. Possible involvement of endothelium-derived hyperpolarizing factor (EDHF) in the depressor responses to platelet activating factor (PAF) in rats. Br J Pharmacol 2000; 131:1113-1120.
26. Kawabata A, Nakaya Y, Kuroda R, Wakisaka M, Masuko T, Nishikawa H, Kawai K. Involvement of EDHF in the hypotension and increased gastric mucosal blood flow caused by PAR-2 activation in rats. Br J Pharmacol 2003; 140:247-254.
27. Yousif MH, Cherian A, Oriowo MA. Endothelium-dependent relaxation in isolated renal arteries of diabetic rabbits. Auton Autacoid Pharmacol 2002; 22:73-82.
28. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle [Review]. Am J Physiol Cell Physiol 1995; 268:C799-C822.
29. Nilius B, Droogmans G. Ion channels and their functional role in vascular endothelium [Review]. Physiol Rev 2001; 81:1415-1459.
30. Herrington J, Hille B. Growth hormone-releasing hexapeptide elevates intracellular calcium in rat somatotrophs by two mechanisms. Endocrinology 1994; 135:1100-1108.
31. Vequaud P, Thorin E. Endothelial G protein beta-subunits trigger nitric oxide - but not endothelium-derived hyperpolarizing factor-dependent dilation in rabbit resistance arteries. Circ Res 2001; 89:716-722.
32. Tschop M, Weyer C, Tattaranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50:707-709.